Dr Louie Chester Lawson Jr, MD | |
1514 Mud Bridge Rd, Buffalo, SC 29321-2411 | |
(843) 602-1460 | |
Not Available |
Full Name | Dr Louie Chester Lawson Jr |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 1514 Mud Bridge Rd, Buffalo, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669184685 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 12541 (South Carolina) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Louie Chester Lawson Jr, MD 1514 Mud Bridge Rd, Buffalo, SC 29321-2411 Ph: (843) 602-1460 | Dr Louie Chester Lawson Jr, MD 1514 Mud Bridge Rd, Buffalo, SC 29321-2411 Ph: (843) 602-1460 |
News Archive
A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.
The ten studies in this special issue document the substantial and growing burden of dengue in the Americas, Africa and Asia, and the burden of a chikungunya outbreak in India.
Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.
Transgender and gender-diverse adults are three to six times more likely as cisgender adults (individuals whose gender identity corresponds to their sex assigned at birth) to be diagnosed as autistic, according to a new study by scientists at the University of Cambridge's Autism Research Centre.
Omnicell, Inc., a leading provider of system solutions to acute healthcare facilities, today announced a partnership agreement to co-market Sentry Data Systems' Sentinel RCM™ application, which has a sophisticated 340B solution component. Sentry specializes in providing solutions to address a variety of financial challenges found within hospitals and pharmacies while Omnicell's WorkflowRx™ software offers a complete inventory management system for hospital pharmacies.
› Verified 8 days ago